Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0D4CX
|
||||
| Former ID |
DIB012229
|
||||
| Drug Name |
Pegamotecan
|
||||
| Synonyms |
Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Esophageal cancer [ICD9: 150; ICD10:C15] | Phase 2 | [1] | ||
| Company |
Enzon Pharmaceuticals Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C53H50N6O13
|
||||
| Canonical SMILES |
[C@@]1(C(=O)OCc2c1cc1n(c2=O)Cc2c1nc1c(c2)cccc1)(OC(=O)[<br />C@@H](NC(=O)COCCOCC(=O)N[C@H](C(=O)O[C@@]1(C(=O)OCc2c1c<br />c1n(c2=O)Cc2c1nc1c(c2)cccc1)CC)C)C)CC
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Toposisomerase-1 | Target Info | Inhibitor | [2] | |
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | DNA replication | ||||
| Pathway Interaction Database | Caspase Cascade in Apoptosis | ||||
| WikiPathways | Integrated Pancreatic Cancer Pathway | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00080002) Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction. U.S. National Institutes of Health. | ||||
| REF 2 | A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol. 2009 Jan;63(2):363-70. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.